Compare CECO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | HRMY |
|---|---|---|
| Founded | 1966 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2002 | 2020 |
| Metric | CECO | HRMY |
|---|---|---|
| Price | $52.40 | $28.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $77.75 | $46.70 |
| AVG Volume (30 Days) | 657.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 280.56 | 7.97 |
| EPS | 1.37 | ★ 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $24.84 | $19.87 |
| Revenue Next Year | $11.51 | $12.49 |
| P/E Ratio | $39.64 | ★ $10.46 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $17.57 | $25.52 |
| 52 Week High | $81.72 | $40.87 |
| Indicator | CECO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 29.67 | 31.77 |
| Support Level | $44.68 | $26.36 |
| Resistance Level | $53.73 | $37.38 |
| Average True Range (ATR) | 4.11 | 1.82 |
| MACD | -2.50 | -0.21 |
| Stochastic Oscillator | 1.78 | 21.42 |
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.